Related Experiment Video

Updated: Jul 25, 2026

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy
08:34

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy

Published on: September 25, 2017

Sex-related difference in regression of left ventricular hypertrophy with antihypertensive treatment: the LIFE study

J N Bella1, V Palmieri, K Wachtell

  • 1Weill Medical College of Cornell University, New York, NY, USA. jonnbella@earthlink.net

Journal of Human Hypertension
|March 26, 2004
PubMed

Insights

Antihypertensive treatment reduced left ventricular (LV) hypertrophy more effectively in women than men, despite similar blood pressure reductions. This sex-related difference in LV mass regression warrants further investigation into its mechanisms and prognostic implications.

Area of Science:

  • Cardiology
  • Hypertension Research
  • Sex Differences in Medicine

Background:

  • Left ventricular (LV) structure and function exhibit sex-based differences in hypertension.
  • The impact of sex on the regression of LV hypertrophy during antihypertensive therapy is not well understood.

Purpose of the Study:

  • To investigate whether sex influences the regression of LV hypertrophy in hypertensive patients undergoing antihypertensive treatment.

Main Methods:

  • Analysis of paired echocardiograms from 500 men and 347 women in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
  • Assessment of LV mass changes after 12 months of treatment with either losartan or atenolol-based regimens.
  • Statistical adjustment for baseline LV mass and randomized treatment.

Main Results:

  • Blood pressure and cardiac output were reduced similarly in both sexes.
  • Absolute LV mass reduction was greater in men initially.
  • After adjustment for baseline LV mass and treatment, LV mass regression was significantly greater in women (-33 g) compared to men (-23 g).

Conclusions:

  • Antihypertensive treatment leads to greater regression of LV hypertrophy in women compared to men, independent of baseline LV mass and treatment regimen.
  • The observed sex difference in LV hypertrophy regression requires further research to elucidate underlying mechanisms and clinical significance.

More Related Videos

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure07:13

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure

Published on: April 30, 2020

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...